Cases & Deals

Rgenix raises capital in Series C round

Clients Rgenix, Inc.

Jones Day represented Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, in connection with its issuance of $40 million of Series C Convertible Preferred Stock in a private placement to Lepu Medical, Oceanpine Capital and WuXi AppTec’s Corporate Venture Fund, Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, LLC, and the Partnership Fund for New York City’s Innovate NY Fund and associated entities.